PAA 2.56% 20.0¢ pharmaust limited

Ann: Approval of Dose Escalation of PPL-1 in Human Trial, page-2

  1. 571 Posts.
    lightbulb Created with Sketch. 37
    Great result.... These guys are moving quickly.. What do we think will happen to the share price when the results of this study show that Tumor markers were reduced due to PPL-1?

    The funny thing is, we already know what the results are going to be based on 100% of patients on the lower dose showing reductions in markers....

    ...seems like a no-brainer
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.